MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
MiMedx Group Total Assets 2011-2026 | MDXG
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets MiMedx Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 343 M | 264 M | 239 M | 171 M | 188 M | 202 M | 167 M | 123 M | 121 M | 193 M | 136 M | 109 M | 84.7 M | 35.2 M | 27.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 343 M | 27.1 M | 160 M |
Quarterly Total Assets MiMedx Group
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 291 M | 270 M | 264 M | 244 M | 230 M | 222 M | 239 M | 189 M | 176 M | 168 M | 171 M | 173 M | - | 174 M | 188 M | 181 M | 187 M | 191 M | 202 M | 202 M | 202 M | 202 M | 167 M | 167 M | 167 M | 167 M | 123 M | - | 123 M | 123 M | 121 M | 179 M | 200 M | 188 M | 117 M | 193 M | 193 M | 193 M | 136 M | 136 M | 136 M | 136 M | 109 M | 109 M | 109 M | 109 M | 84.7 M | 84.7 M | 84.7 M | 84.7 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 291 M | 27.1 M | 149 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
7.36 M | $ 2.11 | - | $ 3.29 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
4.32 B | $ 10.42 | - | $ 1.41 B | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Butterfly Network
BFLY
|
256 M | $ 3.91 | - | $ 828 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
CONMED Corporation
CNMD
|
2.33 B | $ 37.41 | - | $ 1.16 B | USA |
 |
Alphatec Holdings
ATEC
|
791 M | $ 12.6 | - | $ 1.89 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
498 M | $ 8.38 | - | $ 602 M |  Israel |
 |
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.96 | 1.02 % | $ 148 M |  France |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
Boston Scientific Corporation
BSX
|
43.7 B | $ 69.79 | - | $ 103 B | USA |
 |
Establishment Labs Holdings
ESTA
|
357 M | $ 63.48 | - | $ 1.88 B |  Costa-rica |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.19 | - | $ 1.33 M | USA |
 |
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.65 | -8.13 % | $ 35.4 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.33 | - | $ 21.5 M | USA |
 |
ClearPoint Neuro
CLPT
|
39.2 M | $ 11.03 | - | $ 298 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
LivaNova PLC
LIVN
|
2.61 B | $ 61.43 | - | $ 3.35 B |  Britain |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
199 M | $ 18.42 | 0.22 % | $ 121 M | USA |
 |
InMode Ltd.
INMD
|
766 M | $ 13.43 | - | $ 868 M | Israel |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
210 M | $ 2.59 | - | $ 152 M | Israel |
 |
Abbott Laboratories
ABT
|
86.7 B | $ 109.95 | - | $ 191 B | USA |
 |
Delcath Systems
DCTH
|
124 M | $ 9.81 | - | $ 351 M | USA |
 |
Bio-Rad Laboratories
BIO
|
9.36 B | $ 261.24 | - | $ 7.37 B | USA |
 |
Insulet Corporation
PODD
|
3.19 B | $ 224.66 | - | $ 15.8 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 9.01 | - | $ 694 M | USA |
 |
Profound Medical Corp.
PROF
|
43.9 M | $ 5.71 | - | $ 180 M | Canada |
 |
AxoGen
AXGN
|
222 M | $ 32.84 | - | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
6.21 B | $ 169.45 | - | $ 12.7 B | USA |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 32.76 | - | $ 4.88 K | USA |
 |
AVITA Medical
RCEL
|
56.4 M | $ 4.62 | 5.0 % | $ 129 M |  Australia |